Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SNAP +21.6%, AVXL +14%, GNW +11.3%, GAIN +10.6%, ACLS +10.3%, DPW +10.2%,NANO +8.2%, KORS +7.8%, SCSC +7.4%, MODN +7.3%, AKAM +7%, ZEN +6.6%, APC+3.7%, MTCH +3.7%, PXD +3.5%, (to divest its properties in South Texas, Raton and the West Panhandle field; terms not disclosed), CG +3.5%, ULTI +3.2%, AI +2.9%, MX +2.7%,USNA +2.5%, NEWR +2.4%, CVCO +2.4%, CTSH +2.2%, JLL +2.1%, DIS +2%, BLL +2%,STO +1.9%, TWO +1.7%, MNTX +1.2%, CAMT +1%, ICE +0.9%, CERN +0.8%, JEC +0.8%
M&A news:
- PERY +12% (WSJ reporting that former exec made $27.50/share bid), SVU +2.6% (activist wants company to consider sale or breakup, according to WSJ), .
Other news:
- NQ +17.9% (rebounding from 44% decline), AVXL +14% (Anavex is using advanced genomic biomarkets in CNS trials; filed to update IND for ANAVEX 2-73 for Rett Syndrome; plans to submit IND for Alzheimer's in 1H18; reports Q1), RIOT +9.7% (continued strength), WYNN +9.5% (CEO/Chairman Steve Wynn steps down; appoints President Matt Maddox as CEO; also - upgraded to Overweight from Neutral at JP Morgan), VSTM +8.6% (submits a NDA to the FDA seeking full approval for its lead product candidate duvelisib), REXX +6.8% (reports Q4 production at the high end of guidance range), EVTC +4.9% (to join S&P SmallCap 600), SGMO +4.6% (Sangamo Therapeutics and Case Western Reserve University announced the award of an $11 million grant from the National Institutes of Health for a planned study of gene-edited T cells), APC +3.7% (increases quarterly dividend to $0.25/share from $0.20/share; authorizes a $500-mln increase to previously announced $2.5 mln share-repurchase program, bringing the total repurchase program to $3.0 bln), REI +3.5% (will replace Boyd Gaming in the S&P SmallCap 600), TWTR +2.9% (following SNAP results), SIGA+2.6% (announces that the FDA has accepted for priority review the company's New Drug Application for its oral formulation of TPOXX), KALA +2.4% (Orbimed discloses the purchase of additional shares), JRVR +2.1% (to join S&P SmallCap 600), CHK +1.3% (average 2017 fourth quarter production projected at 593,000 boe per day), .
Analyst comments:
- NTNX +4.6% (initiated with a Buy at Goldman)
- CLF +4.1% (upgraded to Outperform from Underperform at Credit Suisse)
- ALLT +3.4% (upgraded to Buy from Underperform at BofA/Merrill)
- DISH +2.8% (upgraded to Buy from Neutral at Citigroup)
- CME +1.5% (upgraded to Buy from Neutral at Goldman)
- ANET +1.4% (initiated with a Buy at Goldman)
- ACOR +1.4% (upgraded to Neutral from Sell at Goldman)
- LB +1% (upgraded to Buy from Neutral at Northcoast)